Home › Funds › Dauntless Investment Group, LLC › LCTX
Dauntless Investment Group, LLC position in LCTX
LINEAGE CELL THERAPEUTICS IN · Health Care
Dauntless Investment Group, LLC reported holding 422,500 shares of LCTX (LINEAGE CELL THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$404K, representing 0.41% of its reported portfolio and ranking #30 among its reported holdings. Dauntless Investment Group, LLC has disclosed LCTX holdings in 4 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Dauntless Investment Group, LLC's LCTX position evolved
Dauntless Investment Group, LLC first disclosed a stake in LCTX in Q2 2025 at 1,205,930 shares (US$731K). The position peaked in Q3 2025 at 1,614,100 shares, worth US$2.7M. Across 4 filings, Dauntless Investment Group, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 422,500 shares valued at US$404K — an increase of 422,400 shares quarter over quarter.. Notable position changes include a 34% increase in Q3 2025 (shares fell 1% over the following quarter), a 422400% increase in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.21M | $731.30K | New |
| Q3 2025 | 1.61M | $2.73M | Add |
| Q2 2026 | 100 | $131 | New |
| Q3 2026 | 422.50K | $403.78K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LCTX and 13F data
LCTX (LINEAGE CELL THERAPEUTICS IN) is a Health Care company. 29 other funds we track also report a position in LCTX — the largest reported positions include BROADWOOD CAPITAL INC (US$47.4M), Defender Capital, LLC. (US$6.4M), RAFFLES ASSOCIATES LP (US$5.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LCTX
- BROADWOOD CAPITAL INC 49.56M sh · $47.37M · Q3 2026
- Defender Capital, LLC. 6.65M sh · $6.35M · Q3 2026
- RAFFLES ASSOCIATES LP 5.20M sh · $4.97M · Q3 2026
- Connective Capital Management, LLC 293.62K sh · $280.62K · Q3 2026
More on Dauntless Investment Group, LLC
FAQ
How long has Dauntless Investment Group, LLC held LCTX?
Dauntless Investment Group, LLC has disclosed LCTX holdings in 4 of the last 6 reported quarters, going back to Q2 2025.
What is Dauntless Investment Group, LLC's current position in LCTX?
As of Q3 2026, Dauntless Investment Group, LLC holds 422.50K shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $403.78K, representing 0.41% of its reported portfolio and ranking #30.
Has Dauntless Investment Group, LLC been buying or selling LCTX?
In the latest 13F filing (Q3 2026), Dauntless Investment Group, LLC increased its position in LCTX. The position peaked in Q3 2025 at 1.61M shares.
Which other funds hold LCTX?
Other major institutional holders of LCTX include BROADWOOD CAPITAL INC, Defender Capital, LLC., RAFFLES ASSOCIATES LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.